JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Perrigo Co PLC

Gesloten

SectorGezondheidszorg

22.02 -2.78

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

21.76

Max

22.82

Belangrijke statistieken

By Trading Economics

Inkomsten

38M

-6.4M

Verkoop

-94M

1B

Dividendrendement

4.22

Winstmarge

-0.613

Werknemers

8,379

EBITDA

13M

127M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+39.69% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.22%

2.54%

Volgende dividenddatum

16 sep 2025

Volgende Ex Dividend datum

29 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

352M

3.7B

Vorige openingsprijs

24.8

Vorige sluitingsprijs

22.02

Nieuwssentiment

By Acuity

12%

88%

11 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Perrigo Co PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 jul 2025, 13:01 UTC

Acquisities, Fusies, Overnames

Perrigo to Sell Dermacosmetics Business to KKR With Focus on Streamlining Company

28 feb 2025, 17:42 UTC

Belangrijke Marktbewegers

Perrigo Shares Jump on FDA's Move to Reclassify Wisconsin Infant-Formula Plant

27 feb 2025, 23:52 UTC

Winsten

Perrigo Gets Facility Reclassification From FDA as 4Q Profit, Revenue Fall

14 jul 2025, 12:33 UTC

Acquisities, Fusies, Overnames

Perrigo: Business Generated About 5% of 2024 Adjusted Operating Income >PRGO

14 jul 2025, 12:33 UTC

Acquisities, Fusies, Overnames

Perrigo: Dermacosmetics Branded Business Generated About EUR125 Million Sales in 2024 >PRGO

14 jul 2025, 12:32 UTC

Acquisities, Fusies, Overnames

Perrigo: Deal Proceeds to Further Strengthen Balance Sheet >PRGO

14 jul 2025, 12:31 UTC

Acquisities, Fusies, Overnames

Perrigo: Deal Includes EUR300 Million Upfront Cash, Up to EUR27 Million Contingent Payments >PRGO

14 jul 2025, 12:31 UTC

Acquisities, Fusies, Overnames

Perrigo To Sell Dermacosmetics Branded Business to KKR Investment Vehicle >PRGO

14 jul 2025, 12:30 UTC

Acquisities, Fusies, Overnames

Perrigo Announces Agreement to Divest Dermacosmetics Business for Up to EUR327 Million

Peer Vergelijking

Prijswijziging

Perrigo Co PLC Prognose

Koersdoel

By TipRanks

39.69% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.5 USD  39.69%

Hoogste 40 USD

Laagste 24 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Perrigo Co PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Technische score

By Trading Central

25.22 / 26.85Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

11 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Perrigo Co PLC

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.